Hepatocellular Carcinoma

Nonalcoholic fatty liver disease remains widely undiagnosed, yet early identification and treatment could mitigate long-term risk for CVD, according to a new American Heart Association scientific statement.

Nivolumab alone or in combination with ipilimumab was safe and well-tolerated in patients with resectable hepatocellular carcinoma in the perioperative setting, according to a study published in Lancet Gastroenterology and Hepatology.

The AGA published 11 recommendations for systemic therapy in patients with hepatocellular carcinoma, which were featured in Gastroenterology.

Screening for hepatocellular carcinoma is critical in high-risk patients, according to a presentation at GUILD conference 2022.

The FDA granted orphan drug designation to two investigational T-cell immunotherapies for the treatment of advanced hepatocellular carcinoma.

Molecules in saliva may be highly sensitive and specific noninvasive biomarkers of hepatocellular carcinoma, according to a study published in PeerJ.

Lenvatinib plus transarterial chemoembolization prolonged survival and improved response rates among patients in China with advanced hepatocellular carcinoma, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

The benefit of immune checkpoint inhibitor therapy for hepatocellular carcinoma did not vary by underlying liver disease, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

Use of beta blockers did not affect outcomes among patients treated with immunotherapy for unresectable hepatocellular carcinoma, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

Pembrolizumab conferred a small but statistically significant survival benefit when added to best supportive care as second-line treatment for patients with advanced hepatocellular carcinoma, according to a phase 3 study conducted in Asia.